Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,587 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.
Borlaug BA, Kitzman DW, Davies MJ, Rasmussen S, Barros E, Butler J, Einfeldt MN, Hovingh GK, Møller DV, Petrie MC, Shah SJ, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Núñez J, Perna E, Schou M, Senni M, van der Meer P, Von Lewinski D, Wolf D, Kosiborod MN. Borlaug BA, et al. Among authors: rasmussen s. Nat Med. 2023 Sep;29(9):2358-2365. doi: 10.1038/s41591-023-02526-x. Epub 2023 Aug 27. Nat Med. 2023. PMID: 37635157 Free PMC article.
Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials.
Verma S, David JP, Leiter LA, Michelsen MM, Rasmussen S, Bhatt DL. Verma S, et al. Among authors: rasmussen s. Diabetes Obes Metab. 2023 Aug;25(8):2388-2392. doi: 10.1111/dom.15081. Epub 2023 May 3. Diabetes Obes Metab. 2023. PMID: 37016488 No abstract available.
Neutrophil to lymphocyte ratio predicts cardiovascular events in people with type 2 diabetes: Post hoc analysis of the SUSTAIN 6 and PIONEER 6 cardiovascular outcomes trials.
Verma S, Husain M, Madsen CM, Leiter LA, Kuhlman AB, Vilsbøll T, Rasmussen S, Libby P. Verma S, et al. Among authors: rasmussen s. Diabetes Obes Metab. 2023 Aug;25(8):2398-2401. doi: 10.1111/dom.15088. Epub 2023 May 8. Diabetes Obes Metab. 2023. PMID: 37046366 No abstract available.
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo.
Tuttle KR, Bosch-Traberg H, Cherney DZI, Hadjadj S, Lawson J, Mosenzon O, Rasmussen S, Bain SC. Tuttle KR, et al. Among authors: rasmussen s. Kidney Int. 2023 Apr;103(4):772-781. doi: 10.1016/j.kint.2022.12.028. Epub 2023 Feb 2. Kidney Int. 2023. PMID: 36738891 Free article.
Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial.
Kolkailah AA, Lingvay I, Dobrecky-Mery I, Aharonovich A, David JP, Holse C, Rasmussen S, McGuire DK. Kolkailah AA, et al. Among authors: rasmussen s. Diabetes Obes Metab. 2023 Apr;25(4):1117-1120. doi: 10.1111/dom.14941. Epub 2022 Dec 23. Diabetes Obes Metab. 2023. PMID: 36514266 Free PMC article. No abstract available.
2,587 results